At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 764 enrolled
Drug / intervention
insulin glargine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or NPH Human Insulin.
In Brief
A Phase 3 clinical trial evaluating insulin glargine and NPH human insulin for Diabetes Mellitus, Type 2. Completed, enrolled 764 participants across 2 sites in 2 countries.
Detailed Summary
The primary objective of this study is to compare the percentage of subjects who reach the target HbA1c level (\< or = 7.0% at endpoint) and do not experience symptomatic nocturnal hypoglycemia during treatment with insulin glargine or NPH human insulin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2000
Primary CompletionOct 2001
First PostedApr 2008
TodayJul 2026
First PostedApr 4, 2008
Enrollment StartJan 1, 2000
Primary CompletionOct 1, 2001
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.2 years ago
Interventions
insulin glarginedrug
NPH human insulindrug